Intelligent Computing,
Journal Year:
2023,
Volume and Issue:
2
Published: Jan. 1, 2023
In
recent
years,
advances
in
neuroscience
and
artificial
intelligence
have
paved
the
way
for
unprecedented
opportunities
to
understand
complexity
of
brain
its
emulation
using
computational
systems.
Cutting-edge
advancements
research
revealed
intricate
relationship
between
structure
function,
success
neural
networks
has
highlighted
importance
network
architecture.
It
is
now
time
bring
these
together
better
how
emerges
from
multiscale
repositories
brain.
this
article,
we
propose
Digital
Twin
Brain
(DTB)—a
transformative
platform
that
bridges
gap
biological
intelligence.
comprises
three
core
elements:
structure,
which
fundamental
twinning
process,
bottom-layer
models
generating
functions,
wide
spectrum
applications.
Crucially,
atlases
provide
a
vital
constraint
preserves
brain’s
organization
within
DTB.
Furthermore,
highlight
open
questions
invite
joint
efforts
interdisciplinary
fields
emphasize
far-reaching
implications
The
DTB
can
offer
insights
into
emergence
neurological
disorders,
holds
tremendous
promise
advancing
our
understanding
both
intelligence,
ultimately
propel
development
general
facilitate
precision
mental
healthcare.
Nature,
Journal Year:
2024,
Volume and Issue:
632(8023), P. 131 - 138
Published: July 17, 2024
Abstract
A
single
dose
of
psilocybin,
a
psychedelic
that
acutely
causes
distortions
space–time
perception
and
ego
dissolution,
produces
rapid
persistent
therapeutic
effects
in
human
clinical
trials
1–4
.
In
animal
models,
psilocybin
induces
neuroplasticity
cortex
hippocampus
5–8
It
remains
unclear
how
brain
network
changes
relate
to
subjective
lasting
psychedelics.
Here
we
tracked
individual-specific
with
longitudinal
precision
functional
mapping
(roughly
18
magnetic
resonance
imaging
visits
per
participant).
Healthy
adults
were
before,
during
for
3
weeks
after
high-dose
(25
mg)
methylphenidate
(40
mg),
brought
back
an
additional
6–12
months
later.
Psilocybin
massively
disrupted
connectivity
(FC)
subcortex,
causing
more
than
threefold
greater
change
methylphenidate.
These
FC
driven
by
desynchronization
across
spatial
scales
(areal,
global),
which
dissolved
distinctions
reducing
correlations
within
anticorrelations
between
networks.
Psilocybin-driven
strongest
the
default
mode
network,
is
connected
anterior
thought
create
our
sense
space,
time
self.
Individual
differences
strongly
linked
experience.
Performing
perceptual
task
reduced
psilocybin-driven
changes.
caused
decrease
weeks.
Persistent
reduction
hippocampal-default
may
represent
neuroanatomical
mechanistic
correlate
proplasticity
American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(1), P. 79 - 103
Published: Jan. 1, 2025
MDMA
(i.e.,
3,4-methylenedixoymethamphetamine),
commonly
known
as
"Ecstasy"
or
"Molly,"
has
been
used
since
the
1970s
both
in
recreational
and
therapeutic
settings.
The
Food
Drug
Administration
(FDA)
designated
MDMA-Assisted
Therapy
(MDMA-AT)
a
Breakthrough
for
posttraumatic
stress
disorder
(PTSD)
2017,
FDA
is
requiring
an
additional
phase
3
trial
after
rejecting
initial
New
Application
2024.
Unlike
other
psychedelics,
uniquely
induces
prosocial
subjective
effects
of
heightened
trust
self-compassion
while
maintaining
ego
functioning
well
cognitive
perceptual
lucidity.
While
use
nonmedical
settings
may
still
cause
harm,
especially
due
to
adulterants
when
without
proper
precautions,
conclusions
that
can
be
drawn
from
studies
are
limited
by
many
confounds.
This
limits
extent
which
evidence
related
extrapolated
use.
A
considerable
body
preliminary
suggests
MDMA-AT
delivered
controlled
clinical
setting
safe
efficacious
treatment
PTSD.
After
course
involving
three
administrations
supported
psychotherapy,
67%-71%
individuals
with
PTSD
no
longer
meet
diagnostic
criteria
versus
32%-48%
placebo-assisted
therapy,
endure
at
long-term
follow-up.
review
primarily
aims
distinguish
nonclinical
using
pharmaceutical-grade
further
describes
putative
neurobiological
mechanisms
underlying
its
effects,
MDMA-AT,
considerations
level
public
health
policy,
future
research
directions.
Brain Sciences,
Journal Year:
2025,
Volume and Issue:
15(2), P. 117 - 117
Published: Jan. 25, 2025
Background:
Psychedelics
are
increasingly
recognized
as
a
promising
and
innovative
treatment
strategy
for
several
mental
disorders.
However,
there
is
still
lively
controversy
in
the
medical
community
regards
rationale
of
their
employment,
specifically
indications
potential
dangers.
Methods:
A
comprehensive
literature
search
on
“MEDLINE/PubMed”
“Web
Science”
was
performed
from
inception
to
26
June
2024,
cross-checking
obtained
references.
We
included
all
studies,
i.e.,
both
clinical
preclinical,
that
supplied
original
data.
Results:
initially
total
1083
entries,
813
MEDLINE/PubMed
270
Web
Science.
After
duplicate
elimination,
903
underwent
systematic
selection.
Primary
abstract
screening
yielded
572
candidates
eligibility
assessment
excluded
331
entries
formal
grounds.
Eligibility
led
exclusion
501
titles.
Finally,
70
articles
were
this
review.
Discussion:
Preclinical
evidence
genetic
expression,
histology
behavioral
studies
soundly
consistent
with
psychedelics
possessing
neuroplasticity-inducing
properties.
Despite
methodological
difficulties,
seems
be
inferentially
agreement
preclinical
findings.
it
unclear
whether
“neuroplastic
boost”
induced
by
classic
might
dissociable
psychodysleptic
effects,
thereby
reducing
psychopathological
hazards
implied
these
compounds.
Moreover,
fact
so-called
“relaxation
priors”
should
unconditionally
beneficial
appears
debatable,
further
research
clarify
possible
contraindications
psychedelic
psychoplastogens
within
precision
medicine
perspective.
American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(1), P. 33 - 46
Published: Jan. 1, 2025
Unlike
classical
antidepressants,
psychedelics
such
as
psilocybin
have
been
shown
to
induce
a
rapid
antidepressant
response.
In
the
wake
of
this
development,
interest
has
emerged
in
ultra-fast,
short-acting
5-methoxy-N,N-dimethyltryptamine
(5-MeO-DMT)
and
N,N-dimethyltryptamine
(DMT)
with
expectation
that
these
can
produce
effects
following
an
intense
but
brief
psychedelic
intervention.
The
current
paper
reviews
clinical
pharmacology
5-MeO-DMT
DMT
their
potential
benefits
challenges
treatment
depression.
Both
compounds
display
affinities
for
variety
monoamine
receptors
transporters,
mostly
so
serotonergic
(5HT)
receptors,
including
5HT
American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(1), P. 114 - 125
Published: Jan. 1, 2025
Evidence
suggests
that
psilocybin-assisted
therapy
(PAT)
leads
to
durable
shifts
in
personality
structure.
However,
such
changes
have
yet
be
characterized
disorders
of
addiction.
In
this
secondary
analysis
from
a
randomized
controlled
trial,
the
authors
examined
effect
PAT
on
dimensions
patients
with
alcohol
use
disorder
(AUD),
hypothesizing
would
attenuate
abnormalities
AUD
and
reductions
trait
impulsiveness
associated
lower
drinking.
American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(1), P. 54 - 78
Published: Jan. 1, 2025
The
authors
critically
examine
the
evidence
base
for
psilocybin
administered
with
psychological
support/therapy
(PST)
in
treatment
of
psychiatric
disorders
and
offer
practical
recommendations
to
guide
future
research
endeavors.
